Periprocedural DOAC interruption protocol from PAUSE study
| Characteristic . | Apixaban . | Rivaroxaban . | Dabigatran CrCl ≥50 . | Dabigatran CrCl <50 . | Edoxaban . |
|---|---|---|---|---|---|
| Preprocedural interruption | Days | Days | Days | Days | Not studied |
| Low bleeding risk procedure | 1 | 1 | 1 | 2 | |
| High bleeding risk procedure | 2 | 2 | 2 | 4 | |
| Postprocedural resumption | |||||
| Low bleeding risk procedure | 1 | 1 | 1 | 1 | |
| High bleeding risk procedure | 2-3 | 2-3 | 2-3 | 2-3 |
| Characteristic . | Apixaban . | Rivaroxaban . | Dabigatran CrCl ≥50 . | Dabigatran CrCl <50 . | Edoxaban . |
|---|---|---|---|---|---|
| Preprocedural interruption | Days | Days | Days | Days | Not studied |
| Low bleeding risk procedure | 1 | 1 | 1 | 2 | |
| High bleeding risk procedure | 2 | 2 | 2 | 4 | |
| Postprocedural resumption | |||||
| Low bleeding risk procedure | 1 | 1 | 1 | 1 | |
| High bleeding risk procedure | 2-3 | 2-3 | 2-3 | 2-3 |
For procedural bleeding risk stratification, we suggest using society-based guidance in the appendix to the ACC consensus decision pathway18 or categorization from PAUSE study.30
CrCl, creatinine clearance.